The first continuous, non-invasive system for biochemical cell-stress monitoring in everyday life — democratising lab diagnostics for the consumer health market.
Despite more than one billion active wearables worldwide, a critical information gap at the cellular level persists. Today's devices capture only macroscopic parameters — HRV, sleep, activity — while the biochemical basis of vitality remains invisible.
Lab diagnostics are precise but expensive and slow, making them unsuitable for continuous everyday monitoring. There is no closed feedback loop between lifestyle choices and molecular response. BCG, MedTech Innovation Report, 2022
Cell Health Stix bridges this gap by democratising lab diagnostics. The user dips a test strip into a urine sample, photographs it with a smartphone, and the app translates the colour reactions — via CIELAB colour-metric analysis — into an intuitive cell-stress index.
Malondialdehyde (MDA) is a byproduct of lipid peroxidation of unsaturated fatty acids and correlates directly with cellular damage caused by oxidative stress. As a clinically validated marker it has served as the gold standard in research for decades.
The underlying detection method is fully peer-reviewed: Bahavarnia et al. (RSC Advances, 2023) demonstrate the feasibility of low-cost, non-invasive test systems using paper-based diagnostics with silver nanoprisms (AgNPrs), achieving a lower limit of quantification of 0.12 µM MDA in urine samples. The study further validates the naked-eye colour-shift sequence — from sea blue through violet, pink, and taupe to orange/yellowish-grey — as a reliable semi-quantitative readout, directly forming the colour scale used in the Cell Health Stix app.
The colour change is caused by morphological transformation of the triangular AgNPrs into circular nanodisks in the presence of MDA, inducing a measurable blue shift in the in-plane dipole resonance peak (LSPR). This phenomenon is highly sensitive, concentration-dependent, and stable for at least 30 days. Bahavarnia et al., RSC Adv., 2023, 13, 30499
To compensate for the variability in urine concentration due to hydration, the system pairs MDA with creatinine as a reference marker. The MDA-to-creatinine quotient normalises hydration status and delivers robust, comparable values regardless of fluid intake. Barr et al., Environmental Health Perspectives, 2005
The actual innovation lies in the systemic combination of three properties not previously united: direct biochemical measurement, continuous everyday usability, and data-driven interpretation. Smartphone cameras now achieve lab quality for colorimetric analysis — the technological foundation for longitudinal monitoring far beyond occasional lab visits. McKinsey, Digital Health Trends, 2021
The target market sits at the intersection of lab diagnostics, wearables and home diagnostics — a category described as "Next-Generation Personal Health Monitoring." IQVIA, Digital Health Trends, 2023
Digital Health is growing at >15 % p.a., driven by the structural shift from curative to preventive medicine. The global wellness economy is projected to reach USD 9.8 trillion by 2029. Global Wellness Institute, 2025
Four tailwinds: miniaturisation of complex diagnostics via nanomaterials, rising out-of-pocket spending in the longevity segment, IVDR regulation raising barriers for late entrants, and growing willingness to pay for data-driven self-optimisation. CB Insights, 2023
| Competitor | Type | Gap |
|---|---|---|
| Everlywell / LetsGetChecked | D2C diagnostics | Point-in-time, no monitoring |
| Vivoo / Vessel Health | Lifestyle tracker | Superficial biomarkers |
| Apple / Oura / Garmin | Wearables | Indirect physiology only |
| Clinical lab | Diagnostics | Expensive, days of waiting |
| Cell Health Stix | USP | Continuous · clinically validated · everyday-ready |
The detection method is fully peer-reviewed and validated in human urine samples (Bahavarnia et al., RSC Advances, 2023). The web app, colorimetric algorithm and trend dashboard are live and testable today.
The next critical milestone is the physical manufacturing of the AgNPrs test strip matrix — transitioning from the validated laboratory protocol to a reproducible, everyday-stable consumable. This requires funding for lab-scale synthesis, matrix stabilisation under field conditions, and IP protection of the proprietary formulation.
We have already opened a waitlist for our planned alpha tester cohort launching in October 2026. Alpha users will receive early access to the full system — test strips, reader and app — and contribute real-world measurement data to validate performance under field conditions.
The alpha cohort will focus on our core target segments: biohackers, high-performance athletes and health-conscious early adopters in the DACH region, who have established willingness to pay for data-driven health tools.
The model pairs a low-friction hardware entry point with a high-margin recurring revenue stream. The Reader minimises the adoption barrier. Test strips form the central revenue driver. The analytics subscription maximises customer lifetime value through longitudinal data network effects.
Algorithms improve cumulatively with growing user numbers — the resulting proprietary longitudinal MDA database creates a sustainable moat that is difficult to replicate. Varian, Information Rules, 1999
Initial go-to-market via D2C direct sales (performance marketing + content). From Year 3 expansion to B2B2C via fitness platforms and corporate wellness to structurally reduce customer acquisition costs. Long-term: licensing of the data platform to insurers and research partners.
Responsible for biochemical product validation, experimental strategy and evidence-based user insights.
Focus on business model scaling, capital strategy and regulatory positioning (IVDR roadmap).
Network: Start-up Center Tübingen · START Munich
The organisation is structured not around classical functions but around core system components: test chemistry, reader, software platform and business model. This enables the tight coupling of product development and data-driven iteration that technology-driven start-ups require.
Location: Tübingen — a university-adjacent innovation cluster with direct access to talent in biochemistry and data science. Active integration into Start-up Center Tübingen and START Munich.
Make-or-Buy: Biochemical development, colour-analysis algorithms and product strategy remain in-house. Hardware manufacturing, regulatory consulting and specialised software development are outsourced — maximum scalability with focused capital deployment.
Headcount follows a phased model: lean core team during the validation phase, targeted expansion into growth, customer success and data science post-launch.
Sustainability is not a CSR add-on but an integral part of product design and supply chain strategy. By making oxidative-stress measurement accessible in daily life, we create the foundation for evidence-based behavioural decisions — directly contributing to reducing chronic disease burden on healthcare systems.
No single-use plastic from the R&D phase onward. IVDR and European Green Deal integrated into product architecture from day one. ESG KPIs reviewed semi-annually.
Test-chemistry development, Reader prototype, App base (CIELAB / OpenCV) → Functional prototype
Reproducibility, AgNPrs stability testing, real-world field test → Validated alpha product
DACH launch, D2C build-up, IVDR classification → Market entry & scaling
Critical path: Test-chemistry validation → system integration → pilot validation. Parallel workstreams: software iteration, app design, hardware engineering. Buffer periods at critical interfaces ensure IVDR conformity without cascade delays. Bahavarnia et al., 2023 · PMI, 2021